Investigators trained four machine-learning classifiers to predict pacing-induced cardiomyopathy in a prospectively assembled multicenter registry. The algorithms included logistic regression, support vector machine, random forest and XGBoost. Models were evaluated using stratified 4-fold cross-validation with hyperparameter optimization, according to the report. XGBoost achieved the highest discriminative performance in the cohort: reported area under the receiver-operating characteristic curve (AUROC) was 0.831, with sensitivity 0.805 and specificity 0.845. Short statement: the study team observed clinically meaningful discrimination for PICM using ML techniques.
Performance metrics were presented at the model level only; the source did not report external validation in an independent dataset. The article did not provide detailed calibration statistics or decision-curve analysis in the text available, so the degree to which these models would translate to clinical decision thresholds beyond the study cohort remains unspecified by the authors.
The univariable Cox regression performed by the authors identified several variables associated with incident PICM. Male sex, pre-implant minimum QTc interval, and post-implant maximum QRS duration were each significantly associated with the outcome in their analysis. Feature-importance examination from the ML pipeline ranked baseline LVEF and post-implant maximum QRS duration as the most influential predictors for the best-performing model.
These observations align with mechanistic hypotheses about chronic right ventricular pacing: worsened ventricular activation (reflected in prolonged QRS) and lower baseline systolic function plausibly increase vulnerability to pacing-related deterioration. The data indicated associations rather than causation; the source did not present multivariable-adjusted hazard ratios or interaction analyses in the summary available.
The analysis used the RISK-PICM registry covering January 2002 to January 2026. The final analytic sample included 125 patients with atrioventricular block (AVB) who underwent pacemaker implantation and had baseline mildly reduced or preserved LVEF, per the authors.
The prespecified outcome, pacing-induced cardiomyopathy, was defined by the study team as a reduction in LVEF of 10% or more resulting in an LVEF below 50%. Over a median follow-up of 4.8 years, 41 of 125 patients (32.8%) developed PICM. The registry and analysis were prospective and multicenter, and the authors reported Institutional Review Board approval for the study.
The published account did not disclose granular baseline demographic breakdowns, device programming details, or site-by-site enrollment counts in the text available. The absence of those specifics constrains interpretation of generalizability across device types and implantation practices.
Model-derived risk stratification was applied in the cohort. The investigators reported that the risk groups generated by their algorithm produced statistically significant separation on Kaplan-Meier analysis (P < 0.001). That separation suggests the classifier distinguished patients with higher versus lower observed PICM incidence over time in this dataset.
According to feature-importance analysis, baseline LVEF and post-implant maximum QRS duration carried the most predictive weight for the best-performing XGBoost model. The authors also highlighted male sex and QTc metrics as contributing variables. The paper did not provide the exact feature-importance values or a complete ranked list in the abstracted text, and preprocessing steps for continuous variables were not described in the available report.
The study was reviewed and approved by the Institutional Review Board of Chung-Ang University Hospital (Approval No. 2018-006-474), and the authors noted trial registration (Clinical Trial NCT03475498). The corresponding author indicates that data supporting the findings are available on reasonable request.
One author, Ki-Woon Kang, is listed as CEO and founder of MitoKey; the company provided support for research analysis for this study. The remaining authors declared no competing interests in the source document.
The report is clear about internal model performance but leaves several implementation questions unanswered. External validation in independent cohorts was not reported in the available text, so transportability to other practice settings remains unknown. The article did not detail model calibration metrics, the full set of candidate variables, or preprocessing and imputation strategies used for missing data. Device programming, pacing burden thresholds, and longitudinal medication adjustments were not described, limiting causal inference about modifiable contributors to PICM.
Practical questions remain: does an ML-derived risk estimate improve patient selection for alternate pacing strategies, and can using the model prospectively reduce PICM incidence? The authors proposed that ML models may support individualized pacing strategy selection, but the source did not report prospective implementation or randomized testing. These gaps define the next specific clinical steps: independent external validation, reporting of calibration and decision-analytic metrics, and prospective trials testing whether model-guided pacing choices change outcomes.